A Sense of Déjà Vu: The Debate Surrounding State Biosimilar Substitution Laws

Description:

The Affordable Care Act created an approval pathway for less expensive generic versions of biologic drugs, known as biosimilars, or follow-on biologics. This Insight on the Issues discusses controversial new state legislation that could greatly limit the savings from biosimilars and notes similarities to the debate ignited by the passage of federal legislation that encouraged the development of traditional generic drugs.

Source: AARP Public Policy Institute

Download full pdf publication | Read more on AARP Public Policy webpage

New Resosurce: Open States

Open States lets you find information about your state representatives and legislation: identify your representative, search and track legislation, explore bill history and votes and contact lawmakers.

Video Tutorial:
Openstates.org is a free tool and makes both their bulk data and api available for others to use.